Perimenopause and Menopause Essentials

Perimenopause marks the transition toward the final menstrual period, often with irregular cycles and vasomotor symptoms. Menopause is clinically defined after twelve months without menstruation.

Genitourinary syndrome of menopause includes dryness, irritation, and urinary urgency that respond to local estrogen or moisturizers in many cases.

Systemic hormone therapy remains an option for healthy candidates with moderate to severe symptoms after individualized risk assessment. Non-hormonal medications and cognitive behavioral strategies also help hot flashes.

Bone density, cardiovascular risk, and mood changes deserve holistic follow-up. Lifestyle—strength training, calcium, vitamin D, and smoking cessation—supports long-term health.

The transition, stage by stage

Perimenopause is the years-long transition before periods stop, marked by fluctuating hormones and often irregular cycles, hot flashes, sleep disruption, and mood changes. Menopause itself is confirmed after twelve consecutive months without a period. Symptoms and their intensity vary widely, and many are manageable.

Managing symptoms and long-term health

Options range from lifestyle measures—layered clothing, regular exercise, limiting alcohol and caffeine—to hormone therapy and non-hormonal medications for those who need them. Because estrogen decline affects bone and heart health, this is a good time to discuss bone density, blood pressure, and cardiovascular risk with a clinician. Vaginal dryness responds well to moisturizers and local estrogen.

The Hormonal Transition From Perimenopause to Postmenopause

Perimenopause begins when the ovaries start producing oestrogen less consistently, typically in the mid-to-late forties, though it can begin earlier. The transition is not a linear decline — oestrogen levels fluctuate wildly during perimenopause, sometimes spiking higher than premenopausal levels before declining. This hormonal volatility, rather than simple deficiency, is responsible for many of the most disruptive early symptoms including unpredictable mood changes, breast tenderness, and irregular periods.

Menopause itself is defined retrospectively as twelve consecutive months without a menstrual period. The average age at natural menopause in high-income countries is around 51 to 52 years. The postmenopausal phase follows, during which oestrogen levels stabilise at a low level and many acute vasomotor symptoms improve, though genitourinary changes tend to persist and progress without intervention. Understanding these three distinct phases — perimenopause, menopause, and postmenopause — helps set realistic expectations about which symptoms to expect when.

Vasomotor Symptoms: Hot Flushes and Night Sweats Explained

Hot flushes are the most reported menopausal symptom, affecting up to 75 % of women during the transition. They arise because declining oestrogen narrows the thermoneutral zone — the temperature range within which the body does not activate sweating or shivering. A relatively small rise in core body temperature triggers a disproportionate sweating response. The flush typically begins with a sudden sense of heat in the chest and face, flushing of the skin, and profuse sweating, followed by a chill as the body overcorrects. The episode usually lasts two to four minutes.

Night sweats are nocturnal hot flushes and can cause significant sleep disruption, which cascades into fatigue, cognitive difficulties, and mood disturbance. Practical environmental interventions — sleeping in a cool room (around 18 °C), using moisture-wicking bedding, keeping a small fan beside the bed, and wearing layered, breathable clothing — can reduce episode severity and frequency. Keeping a glass of cold water on the bedside table to sip during night sweats is a simple but effective comfort measure.

Genitourinary Syndrome of Menopause (GSM): More Than Dryness

Genitourinary syndrome of menopause (GSM) is the current clinical term for a cluster of symptoms caused by oestrogen deficiency in the vulva, vagina, and lower urinary tract. Unlike hot flushes, which often improve over time, GSM tends to worsen progressively without treatment. Symptoms include vaginal dryness, reduced lubrication during arousal, vaginal burning or irritation, pain during sex (dyspareunia), urinary urgency, frequency, recurrent UTIs, and urinary leakage. These symptoms significantly impact quality of life and yet are underreported because people assume they are an unavoidable part of ageing.

Vaginal oestrogen — available as pessaries, cream, or a ring — applied locally delivers very low doses directly to genital tissue. Because systemic absorption is minimal, vaginal oestrogen is considered safe for the vast majority of postmenopausal people, including many who cannot use systemic hormone therapy. It gradually restores vaginal epithelial thickness, improves lubrication, lowers vaginal pH back toward the premenopausal protective range, and reduces recurrent UTI incidence. Benefits typically become noticeable within four to twelve weeks of consistent use and are sustained with ongoing treatment.

Menopausal Hormone Therapy: Benefits, Risks and Evolving Evidence

Menopausal hormone therapy (MHT), previously called HRT, is the most effective treatment for moderate-to-severe vasomotor symptoms and also protects bone density, reduces risk of type 2 diabetes, and improves quality of life for many people. The risks of MHT are dose- and formulation-dependent and have been substantially clarified since the early 2000s Women's Health Initiative study, whose findings were initially over-extrapolated. Current evidence supports that for healthy women under 60 or within ten years of menopause onset, the benefits of MHT generally outweigh the risks.

Transdermal oestrogen (patches, gels, or sprays) avoids first-pass liver metabolism and is associated with lower risks of venous thromboembolism and stroke compared to oral oestrogen — an important distinction for individuals with cardiovascular risk factors. People who have not had a hysterectomy require progestogen alongside oestrogen to protect the endometrium; micronised progesterone appears to carry a more favourable breast cancer risk profile than synthetic progestins. MHT decisions should be individualised, regularly reviewed, and informed by a thorough discussion of personal health history with a knowledgeable clinician.

Bone Health and Cardiovascular Changes After Menopause

Oestrogen plays a central role in maintaining bone density by inhibiting osteoclast activity (bone breakdown). The years immediately surrounding the menopause transition are a period of accelerated bone loss — up to 2 % per year — which subsides but continues more slowly in the postmenopausal decades. This cumulative loss significantly increases osteoporosis risk. Preventive strategies include adequate calcium intake (1000–1200 mg daily from food and supplements combined), vitamin D sufficiency, weight-bearing and resistance exercise, avoiding smoking, and limiting alcohol. A DEXA scan to assess bone mineral density is appropriate for those with risk factors.

Premenopausal oestrogen also has cardiovascular protective effects: it maintains favourable lipid profiles, supports endothelial function, and reduces arterial stiffness. After menopause, LDL cholesterol typically rises, HDL may fall, and cardiovascular risk increases progressively. This makes the postmenopausal decades a critical window for cardiovascular risk factor management — blood pressure monitoring, maintaining a healthy weight, regular aerobic exercise, and a diet rich in vegetables, legumes, whole grains, and healthy fats become especially important.

Non-Hormonal Options for Symptom Management

For those who cannot or prefer not to use MHT, several evidence-based non-hormonal options exist. Selective serotonin and noradrenaline reuptake inhibitors (SSRIs and SNRIs) — particularly venlafaxine, paroxetine, and escitalopram — reduce hot flush frequency by approximately 50–60 %. Gabapentin has similar efficacy and can also improve sleep. Oxybutynin, a bladder medication, has shown benefit for vasomotor symptoms in clinical trials. Fezolinetant, a neurokinin-3 receptor antagonist, is a newer non-hormonal option specifically approved for menopausal hot flushes in several countries.

Cognitive behavioural therapy (CBT) delivered in a menopause-specific format has robust evidence for reducing the burden of hot flushes and night sweats, improving sleep, and reducing anxiety. It works by changing the interpretation of and behavioural response to symptoms rather than their frequency. Mindfulness-based stress reduction (MBSR) and paced breathing techniques also help reduce flush severity in practice. These psychological approaches are especially valuable as standalone or adjunctive treatments.

Frequently Asked Questions

Q: How long do menopausal symptoms last? A: On average, vasomotor symptoms last seven to ten years, but there is enormous individual variation. Some people experience mild symptoms for one to two years; others have significant symptoms well into their sixties. Earlier age of menopause onset and higher symptom severity at perimenopause are associated with longer symptom duration. Effective treatment is available regardless of how long symptoms last.

Q: Is premature menopause (before age 40) the same as normal menopause? A: Premature ovarian insufficiency (POI) is distinct from natural menopause and carries additional health implications, particularly for cardiovascular and bone health, due to the longer period of oestrogen deficiency. Hormone therapy is recommended until at least the average age of natural menopause (around 51) for people with POI, unless contraindicated, to mitigate these long-term risks.

Q: Can I still get pregnant during perimenopause? A: Yes. Although fertility declines significantly during perimenopause, ovulation can still occur sporadically. Contraception is recommended until twelve months after the last menstrual period for those over 50, and twenty-four months for those under 50, if pregnancy is not desired. The progestogen-only pill, hormonal IUD, copper IUD, and barrier methods are all suitable options during perimenopause.

Q: Does menopause cause weight gain? A: The hormonal transition shifts fat distribution — favouring abdominal deposition over peripheral (hip and thigh) deposition — even without significant total weight change. Metabolic rate also declines modestly with age. Many people do gain weight during the menopausal transition, but caloric excess and reduced physical activity are the primary drivers rather than menopause itself. Resistance training is particularly important during this period for maintaining lean muscle mass and metabolic rate.